Publicaciones científicas

100 Publicaciones científicas disponibles

  • Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

    1 de octubre de 2020 | Revista: JAMA Oncology

    Thomas Yau  1 , Yoon-Koo Kang  2 , Tae-You Kim  3 , Anthony B El-Khoueiry  4 , Armando Santoro  5 , Bruno Sangro  6 , Ignacio Melero  7 , Masatoshi Kudo  8 , Ming-Mo Hou  9 , Ana Matilla  10 , Francesco Tovoli  11 , Jennifer J Knox  12 , Aiwu Ruth He  13 , Bassel F El-Rayes  14 , Mirelis Acosta-Rivera  15 , Ho-Yeong Lim  16 , Jaclyn Neely  17 , Yun Shen  18 , Tami Wisniewski  19 , Jeffrey Anderson  19 , Chiun Hsu  20


  • Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

    22 de julio de 2020 | Revista: Journal of Hepatology

    Bruno Sangro  1 , Ignacio Melero  2 , Samir Wadhawan  3 , Richard S Finn  4 , Ghassan K Abou-Alfa  5 , Ann-Lii Cheng  6 , Thomas Yau  7 , Junji Furuse  8 , Joong-Won Park  9 , Zachary Boyd  3 , Hao Tracy Tang  3 , Yun Shen  3 , Marina Tschaika  3 , Jaclyn Neely  3 , Anthony El-Khoueiry  10

    (1) Clinica Universidad de Navarra-IDISNA and CIBEREHD, Pamplona, Spain.
    (2) Universidad de Navarra, Pamplona, Spain.
    (3) Bristol Myers Squibb, Princeton, NJ, USA.
    (4) University of California, Los Angeles, CA, USA.
    (5) Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA.
    (6) National Taiwan University Hospital, Taipei, Taiwan.
    (7) University of Hong Kong, Hong Kong, China.
    (8) Kyorin University Faculty of Medicine, Tokyo, Japan.
    (9) National Cancer Center, Goyang, South Korea.
    (10) USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.


  • Cancer immunotherapy resistance based on immune checkpoints inhibitors

    15 de julio de 2020 | Revista: Drug Resistance Updates

    Elisabeth Pérez-Ruiz  1 , Ignacio Melero  2 , Joanna Kopecka  3 , Ana Bela Sarmento-Ribeiro  4 , Marilina García-Aranda  5 , Javier De Las Rivas  6

    (1) Medical Oncology Department, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Costa del Sol, 29603 Marbella, Malaga, Spain. 
    (2) Immunology and Immunotherapy Department, Clinica Universidad de Navarra (CUN), Center for Applied Medical Research (CIMA), Universidad de Navarra (UNAV), 31008 Pamplona, Spain.
    (3) Department of Oncology, Turin School of Medicine, University of Turin, 10126 Turin, Italy.
    (4) Laboratory of Oncobiology and Hematology and University Clinic of Hematology and Coimbra Institute for Clinical and Biomedical Research - Group of Environment Genetics and Oncobiology (iCBR/CIMAGO), Faculty of Medicine, University of Coimbra (FMUC), and Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Portugal.
    (5) Research Unit, Hospital Costa del Sol, Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC) and Instituto de Investigación Biomédica de Málaga (IBIMA), 29603 Marbella, Malaga, Spain.
    (6) Cancer Research Center (CiC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), and Instituto de Investigación Biomédica de Salamanca (IBSAL), 37007 Salamanca, Spain.


  • New Emerging Targets in Cancer Immunotherapy: CD137/4-1BB Costimulatory Axis

    1 de julio de 2020 | Revista: ESMO Open

    Iñaki Etxeberria (1) , Javier Glez-Vaz (2) , Álvaro Teijeira (2) , Ignacio Melero (2, 3)

    (1) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Navarra, Spain
    (2) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Navarra, Spain.
    (3) Department of Immunology, Clinica Universidad de Navarra, Pamplona, Navarra, Spain.

SOLICITE